Literature DB >> 12088172

Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs.

W Victor R Vieweg1.   

Abstract

This article reviews cardiac electrophysiology, with a focus on the assessment of the electrocardiographically determined corrected QT (QTc) interval and its role as a marker for potentially life-threatening cardiac arrhythmias such as torsades de pointes. Presently, using the QTc interval as a surrogate for polymorphic ventricular tachycardia is handicapped, in part, by the limitations of currently available group-derived formulas to estimate the QTc interval. Regulatory agencies have sharpened their interest in this arena. Substantial progress almost certainly awaits the application of individual rather than group-derived formulas to estimate the QTc interval. Until this refinement arrives, clinicians are advised to exercise caution when administering antipsychotic drugs with the potential to significantly prolong the QT interval. Caution is particularly urged in patients with cardiovascular disease or risk factors for cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12088172

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

1.  Knowledge deficits related to the QT interval could affect patient safety.

Authors:  Nancy M Allen LaPointe; Sana M Al-Khatib; Judith M Kramer; Robert M Califf
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-04       Impact factor: 1.468

2.  A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients.

Authors:  Andrew J Muzyk; Sarah K Rivelli; Wei Jiang; Heather Heinz; Amber Rayfield; Jane P Gagliardi
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

3.  Antipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents: results from a nested case-control study.

Authors:  Christoph U Correll; Jennifer Harris; Vicki Figen; John M Kane; Peter Manu
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-08-08       Impact factor: 2.576

4.  Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics.

Authors:  Fu De Yang; Xiang Qun Wang; Xiu Ping Liu; Ke Xin Zhao; Wei Hong Fu; Xue Ru Hao; Xing Li Zhang; Guo Shu Huang; Sheng Cai Qu; Jing Shen Bai; Xu Feng Huang; Thomas R Kosten; Xiang Yang Zhang
Journal:  Psychopharmacology (Berl)       Date:  2011-02-09       Impact factor: 4.530

Review 5.  Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.

Authors:  W Victor R Vieweg; Mark A Wood; Antony Fernandez; Mary Beatty-Brooks; Mehrul Hasnain; Anand K Pandurangi
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 6.  Ziprasidone in the management of schizophrenia : the QT interval issue in context.

Authors:  David Taylor
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

7.  New Generation Antipsychotic Drugs and QTc Interval Prolongation.

Authors:  W VictorR Vieweg
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-10

Review 8.  Micro-electrode arrays in cardiac safety pharmacology: a novel tool to study QT interval prolongation.

Authors:  Thomas Meyer; Karl-Heinz Boven; Elke Günther; Michael Fejtl
Journal:  Drug Saf       Date:  2004       Impact factor: 5.228

9.  Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders.

Authors:  Stan Kutcher; Sarah J Brooks; David M Gardner; Bill Honer; Lili Kopala; Alain Labelle; Pierre Lalonde; Ashok Malla; Heather Milliken; Jorge Soni; Richard Williams
Journal:  Neuropsychiatr Dis Treat       Date:  2005-06       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.